Although our current study developed HCC tumors with PTEN and CDKN2A loss-of-function mutations, the system is readily adaptable to develop HCC with other mutational profiles in Oncopigs (Elkhadragy et al., 2020). This evidence concerns the gene PTEN and hepatocellular carcinoma.